| Literature DB >> 29552622 |
Yuta Kasagi1, Prasanna M Chandramouleeswaran2,3, Kelly A Whelan2,3, Koji Tanaka2,3, Veronique Giroux2,3, Medha Sharma2,3, Joshua Wang1, Alain J Benitez1, Maureen DeMarshall2, John W Tobias4, Kathryn E Hamilton2,3, Gary W Falk2, Jonathan M Spergel5,6, Andres J Klein-Szanto7, Anil K Rustgi2,3, Amanda B Muir1,6, Hiroshi Nakagawa2,3.
Abstract
BACKGROUND & AIMS: Aberrations in the esophageal proliferation-differentiation gradient are histologic hallmarks in eosinophilic esophagitis (EoE) and gastroesophageal reflux disease. A reliable protocol to grow 3-dimensional (3D) esophageal organoids is needed to study esophageal epithelial homeostasis under physiological and pathologic conditions.Entities:
Keywords: 3D, 3-dimensional; BCH, basal cell hyperplasia; DAPI, 4′,6-Diamidino-2-Phenylindole, Dihydrochloride; DNMAML1, dominant negative MAML1; DOX, doxycycline; EGF, epidermal growth factor; EMT, epithelial-mesenchymal transition; EoE, eosinophilic esophagitis; Eosinophilic Esophagitis; GERD, gastroesophageal reflux disease; GFP, green fluorescent protein; GSI, γ-secretase inhibitor; H&E, hematoxylin and eosin; IF, immunofluorescence; IHC, immunohistochemistry; IL, interleukin; IVL, Involucrin; KSFM, keratinocyte SFM; KSFMC, KSFM containing 0.6 mM Ca2+; Keratinocytes; MAML1, Mastermind-like protein1; OFR, organoid formation rate; Squamous Cell Differentiation; TNF-α, tumor necrosis factor-α; Three-Dimensional; Tslp, thymic stromal lymphopoietin; aDMEM/F12, advanced Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12; qRT-PCR, quantitative reverse-transcription polymerase chain reaction
Year: 2018 PMID: 29552622 PMCID: PMC5852293 DOI: 10.1016/j.jcmgh.2017.12.013
Source DB: PubMed Journal: Cell Mol Gastroenterol Hepatol ISSN: 2352-345X
Patients Used to Generate Biopsy-Derived Esophageal 3D Organoids
| # | Age | Sex | Diagnosis | Passage |
|---|---|---|---|---|
| 1 | 15 | M | Normal | n.d. |
| 2 | 5 | M | Inactive | n.d. |
| 3 | 8 | M | Inactive | n.d. |
| 4 | 14 | M | Inactive | n.d. |
| 5 | 14 | F | Normal | n.d. |
| 6 | 11 | F | GERD | n.d. |
| 7 | 11 | M | GERD | n.d. |
| 8 | 13 | M | GERD | n.d. |
| 9 | 8 | M | Active | n.d. |
| 10 | 14 | F | Active | n.d. |
| 11 | 16 | M | PPI-REE | 2 |
| 12 | 6 | M | Inactive | 3 |
| 13 | 8 | F | Inactive | n.d. |
| 14 | 11 | M | Inactive | 3 |
| 15 | 5 | M | Active | 4 |
| 16 | 18 | F | Active | 5 |
| 17 | 16 | F | Normal | 3 |
| 18 | 9 | M | Active | 6 |
| 19 | 10 | F | Normal | n.d. |
| 20 | 8 | F | Normal | n.d. |
| 21 | 6 | M | Inactive | 4 |
| 22 | 5 | M | PPI-REE | 5 |
| 23 | 7 | F | Active | 4 |
| 24 | 14 | M | Inactive | 7 |
| 25 | 8 | M | Normal | 4 |
| 26 | 11 | F | Active | 3 |
| 27 | 10 | M | Inactive | 3 |
| 28 | 6 | M | Inactive | n.d. |
| 29 | 8 | M | Inactive | n.d. |
| 30 | 10 | M | Active | 4 |
| 31 | 18 | M | Active | n.d. |
| 32 | 18 | M | Inactive | n.d. |
| 33 | 18 | F | Normal | 4 |
| 34 | 12 | F | Normal | n.d. |
NOTE. Normal, no pathologic diagnosis; inactive, <15 eos/hpf but with previous diagnosis of EoE; GERD, 1–5 eos/hpf; active, >15 eos/hpf.
n.d., not determined; PPI-REE, proton pump inhibitor–responsive esophageal eosinophilia.
3D organoid culture was not passaged after this passage number.
3D organoids failed to grow after this passage number.
Media Constituents
| Media | aDMEM/F12 | KSFMC | KSFM | |
|---|---|---|---|---|
| Base medium | Advanced DMEM/F12 | Keratinocyte-SFM | Keratinocyte-SFM | |
| Supplements | L-glutamine | (+) | (-) | (-) |
| HEPES | (+) | (-) | (-) | |
| Bovine pituitary extract | (-) | 50 μg/mL | 50 μg/mL | |
| Penicillin-streptomycin | (+) | (+) | (+) | |
| Y27632 | 10 μM | 10 μM | 10 μM | |
| N2 supplement | 1x | (-) | (-) | |
| B27 supplement | 1x | (-) | (-) | |
| 1 mM | (-) | (-) | ||
| Noggin/R-Spondin | 3% (vol/vol) | (-) | (-) | |
| Wnt3A | 100 ng/mL | (-) | (-) | |
| A83-01 | 500 nM | (-) | (-) | |
| SB202190 | 10 μM | (-) | (-) | |
| Gastrin | 10 nM | (-) | (-) | |
| Nicotinamide | 10 mM | (-) | (-) | |
| EGF | 50 ng/mL | 1 ng/mL | 1 ng/mL | |
| Calcium chloride | 1.0 mM | 0.6 mM | 0.09 mM | |
Growth supplements in Figure 2.
Figure 2Optimization of normal human and murine esophageal 3D organoid culture. Esophageal 3D organoid culture was optimized with the normal human esophageal epithelial cell line EPC2-hTERT in A–C and wild-type murine esophageal cells dissociated from epithelial sheets in D–F. A single cell suspension was mixed with Matrigel and cultured for 11 days in indicated media supplemented with EGF and insulin. Unique growth supplements used for murine esophageal 3D organoids (ie, Noggin/R-Spondin1-conditioned medium, Wnt3A, A83-01, SB202190, gastrin, and nicotinamide) were added as indicated. KSFM contains 0.09 mM Ca2+ (low Ca2+), whereas KSFMC is supplemented with additional CaCl2 to the final concentration of 0.6 mM Ca2+ (high Ca2+). The aDMEM medium contains 1 mM Ca2+. 3D culture products were photomicrographed under a phase-contrast microscopy and further recovered from Matrigel for H&E staining in A and D. Organoids were defined as 3D structures with a diameter of 50 μm or larger. Note that 3D organoid formation was barely observed in aDMEM/F12 with or without unique supplements. Addition of unique supplements also limited organoid formation in KSFM. 3D organoids grown in KSFM showed a lobular pattern of basaloid cell expansion toward surrounding matrix and had a less explicit differentiation gradient as compared with 3D organoids formed in KSFMC. Average organoid size was determined in B and E. OFR was determined in C and F. Scale bar = 100 μm in phase-contrast images and 50 μm in H&E staining. *P < .0001 vs KSFM with supplements; #P < .05 vs KSFM without supplements; n = 6 in B and n = 8 in C. *P < .05 vs aDMEM/F12; ns, not significant vs aDMEM/F12; n = 6 in E and n = 8 in F. Data represent >2 biologic replicates with similar results. GS, growth supplements.
Figure 1Generation and analyses of biopsy-derived esophageal 3D organoids. Biopsies from normal mucosa were taken at the time of diagnostic upper endoscopy and enzymatically dissociated and filtrated, yielding in 105–106 cells per biopsy. A single cell suspension is mixed with 50% Matrigel to initiate 3D organoid culture in KSFMC medium. The resulting 3D products are passaged, frozen-stocked, and characterized via morphologic and functional assays at P0 or subsequent passages (P1 or later) where organoids are treated with cytokines and pharmacologic agents.
Figure 3Growth kinetics of human esophageal 3D organoids. Human esophageal 3D organoids were generated with EPC2-hTERT cells in KSFMC medium and analyzed for structures and growth properties at indicated time points. The 3D organoid culture products were photomicrographed under a phase-contrast microscopy and recovered from Matrigel for H&E, IHC for Ki-67, and IF for IVL (A). DAPI-stained cell nuclei. Scale bar = 50 μm. Ki-67 labeling index (LI) was determined at each time point (B). *P < .05 vs Day 5; ns, not significant versus Day 5; n = 8. (C) Average organoid size and viable cells were determined by phase-contrast imaging (A) and WST1 assays, respectively. *P < .05 vs Day 1; and †, vs Day 14 in WST1 assays; n = 3. #P < .05 vs Day 5; and ns, not significant vs Day 14 in organoid size; n = 8. Data represent 2 biologic replicates with similar results.
Figure 4Human 3D esophageal organoids from endoscopic biopsies display an explicit proliferation-differentiation gradient . Esophageal 3D organoids derived from patient biopsies and normal esophageal mucosa were grown in KSFMC medium. 3D culture products were photomicrographed under a phase-contrast microscopy and further recovered from Matrigel for H&E, IHC for Ki-67, and IF for IVL in A. H&E- and Ki-67-stained panels show from the periphery to the center, basaloid, intermediate (spinous), and keratinized cells with the very center of the organoid showing a terminally differentiated keratinized core. Only basaloid cells are Ki-67 positive. DAPI-stained cell nuclei in IF. Scale bars = 100 μm in phase-contrast image, 50 μm in H&E staining, IHC, and IF. (B and C) Esophageal 3D organoids were generated from patients with normal esophageal mucosa, GERD, active EoE, and inactive EoE. The resulting 3D organoids were analyzed by H&E staining for morphology in B. Scale bar = 50 μm. Organoid formation rate was determined in organoids derived from normal (n = 8), GERD (n = 3), active EoE (n = 11), and inactive EoE (n = 9) patients in C. ns, not significant vs normal as determined with P < .05 being considered statistically significant. (D) Biopsy-derived primary organoids (P01) were recovered from Matrigel and enzymatically dissociated for flow cytometry. Cell surface expression of CD45 and N-cadherin (N-Cad) were evaluated to determine N-Cad-/CD45- epithelial cells and nonepithelial cell (CD45+ or N-Cad+) as shown in a representative dot plot of normal biopsies: N-Cad-/CD45-, 99.9% ± 0.087, N-Cad+/CD45- 0.0078 ± 0.057%, N-Cad-/CD45+ 0.0046 ± 0.039%; mean ± standard error of the mean, <0.05 vs N-Cad-/CD45-, n = 3). Note that nonepithelial cells were detected minimally (<0.1%). (E) Organoid size was determined at the end of each passage (P0-P3). *P < .01 vs P0; ns, not significant vs P0; n = 8. (F) 3D organoids were first grown in KSFMC and then passaged in KSFMC supplemented with or without SB202190, WNT3A, Noggin/R-Spondin1, or A83-01. OFR was determined at the end of passages 2 and 3. *P < .01 vs P2 or 3 and supplements (-); #P < .05 vs P2 or 3 and Wnt3a; n = 6. There was no organoid growth noted in the presence of SB202190 at the end of P2. Data represent ≥2 biologic replicates with similar results.
Figure 5Genetic and pharmacologic inhibition of Notch signaling increases basaloid cell content in esophageal 3D organoids. Esophageal 3D organoids were generated from biopsies of normal esophageal mucosa and EPC2-hTERT and derivatives (A–C) or C57BL/6J murine esophageal epithelial sheets (D–F). Organoids were grown in the presence or absence of 1 μM compound E, a GSI or dimethyl sulfoxide (vehicle), DNMAML1 or GFP (control vector), 1 μg/mL DOX to turn off DNMAML1 expression in cells expressing transgenic DNMAML1 in DNMAML1. H&E-stained 3D organoids in A were evaluated for basaloid cell content under indicated conditions in B. *P < .01 vs GSI (-), GFP, or DOX (-); n = 6. The 3D organoids were enzymatically dissociated and assessed for CD29 expression by flow cytometry in C. Bar diagram (mean ± standard error of the mean) shows the proportion of cells with high CD29 expression (basaloid cells) and low CD29 expression (differentiated cells) in 3D organoids. *P < .01 vs GSI (-), GFP, or DOX (-); n = 3. (D and E) Murine esophageal 3D organoids were grown in the presence or absence of 1 μM compound E (GSI). (F) Single cell suspensions prepared from epithelial sheets isolated from Notch1 mice were incubated with adenovirus expressing either Cre recombinase (Ad-Cre) to induce Notch1 deletion or GFP (Ad-GFP, negative control) before plating in organoid culture. Organoids were stained by H&E in D. Note that GSI-treated organoids display increased basaloid cell content and abrupt terminal differentiation (keratinization), whereas a clear differentiation gradient is present in GSI-untreated control organoids. Basaloid cell content was determined in H&E-stained organoids in E and F. Basaloid cell content is increased on pan-Notch inhibition with GSI or Ad-Cre-mediated genetic deletion of Notch1. *P < .01 vs GSI (-) or GFP. Data represent 2 biologic replicates with similar results.
Figure 6Pan-Notch inhibition results in suppression of IVL and Notch target genes in human esophageal 3D organoids. Esophageal 3D organoids in Figure 5 were analyzed for IVL expression by IF (A). Organoids were analyzed by qRT-PCR for mRNA expression of NOTCH3, HES5, and IVL. GAPDH served as an internal control *P < .01 vs GFP in B; *P < .01 vs DOX (-) in B; n = 3. Data represent 2 biologic replicates with similar results.
Figure 7Pan-Notch inhibition decreases OFR in murine, but not human, esophageal 3D organoids without affecting basaloid cell proliferation in both human and mice. Human esophageal 3D organoids in Figure 5 were analyzed for Ki-67 expression by IHC under indicated conditions (A and B). Ki-67 labeling index (LI) in A was determined in B. *P < .01 vs GSI (-), GFP, or DOX (-); n = 6. OFR for human (C) and murine (D) esophageal 3D organoids under indicated conditions in Figure 5 was determined. Note that OFR was decreased on pan-Notch inhibition with GSI or Ad-Cre-mediated genetic deletion of Notch1 in (D). ns, not significant vs GSI (-), GFP, or DOX (-); n = 3 in (C). *P < .01 vs GSI (-) or GFP; n = 6 in (D). Data represent 2 biologic replicates with similar results.
Figure 8Notch3 mRNA and ICN1. (A) qRT-PCR was performed to evaluate the mRNA levels of Notch receptor paralogs (Notch1–4) in esophageal biopsies from non-EoE (n = 5) and active EoE (n = 10) patients. ns, not significant vs non-EoE; *P < .05 vs non-EoE. P value was determined by 2-tailed Student t test. Note that Notch4 mRNA was not detectable by PCR. (B) IHC for ICN1Val1744 was performed on biopsies from patients with non-EoE normal esophageal mucosa (n = 5) and active EoE with BCH (n = 4). Arrows indicate nuclear localization of ICN.
Figure 9TNF-α suppresses Notch-dependent transcription, Notch ligands, and Notch1 target genes in human esophageal epithelial cells. Effects of cytokine stimulation were determined in EPC2-hTERT cells in monolayer culture (A and B) and 3D organoids (C and D). (A) Cells were stimulated for 24 hours with or without indicated cytokines either alone or in combination and subjected to immunoblotting for ICN1Val1744. NT, no treatment. β-actin served as a loading control. To measure Notch-dependent transcriptional activity, cells were transfected with 8xCSL-luc reporter construct and then treated with or without 40 ng/mL of TNF-α for 48 hours before cells were lysed for luciferase assays in B. pGL3-Basic was used to determine the background luciferase activity. ns, not significant vs pGL3-Basic and TNF-α (-); *P < .0001 vs pGL3-Basic and TNF-α (-); #P < .0001 vs 8xCSL-luc and TNF-α (-); n = 4. Established 3D organoids were treated with 5 ng/mL TNF-α for 72 hours from Day 5 and subjected to qRT-PCR (C) or immunoblotting (D) for indicated molecules. β-actin served as an internal control. *P < .01 vs TNF-α (-); n = 3 in C. (D) ICN3 denotes the intracellular domain of NOTCH3. (A and D) Numbers under each band represent the signal intensity relative to NT set as 1. Data represent 2 biologic replicates with similar results.
Figure 10TNF-α increases basaloid cell content with a concurrent suppression of Notch target genes in human esophageal 3D organoids. Esophageal 3D organoids were grown for 11 days from normal esophageal mucosa or EPC2-hTERT cells in the presence or absence of 1 ng/mL TNF-α or 1 ng/mL IL13 (D). Resulting 3D organoids were analyzed by H&E staining for morphology in A from which basaloid cell content was determined in B. Scale bars = 50 μm. *P < .0001 vs TNF-α (-); n = 6. (C) 3D organoids were enzymatically dissociated and assessed for CD29 expression. Bar diagram shows the proportion of cells with high CD29 expression (basaloid cells) and low CD29 expression (differentiated cells) in 3D organoids. *P < .0001 vs TNF-α (-); n = 3. (D) Organoids were analyzed for IVL expression by IF. NT, no treatment. (E) EPC2-hTERT 3D organoids grown in the presence or absence of 5 ng/mL TNF-α were harvested at Days 7 and 11. Cell proliferation was assessed by IHC for Ki-67 in from which Ki-67 labeling index (LI) was determined in F. Scale bars = 50 μm. *P < .0001 vs TNF-α (-) at Day 7; ns, not significant vs TNF-α (-) at Day 11; n = 6. Representative images are shown. Scales bars = 50 μm. Data represent 2 biologic replicates with similar results.